Aurinia Pharmaceuticals Stock News

Aurinia Pharma (AUPH) stock is on the rise Thursday as investors hold out hope for a takeover of the company by Novartis (NVS).

Renewed buyout speculation has investors piling into this biotech stock today.

Aurinia Pharma (AUPH) stock is on the rise Thursday as investors hold out hope for a takeover of the company by Novartis (NVS). The post AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) were down 6.2% during trading on Monday . The stock traded as low as $18.09 and last traded at $18.14. Approximately 79,365 shares were traded during trading, a decline of 98% from the average daily volume of 4,285,604 shares. The stock had previously closed at $19.33. Several analysts []

Aurinia Pharmaceuticals Inc (AUPH) shares closed this week 32.1% lower than it did at the end of last week. The stock is currently up 39.8% year-to-date, up 38.3% over the past 12 months, and up 509.8% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Shares traded as high as $29.92 and as low as $17.30 this week.Shares closed 43.1% below its 52-week high and 98.9% above its 52-week low.Trading volume this week was 59.4% lower than the 10-day average and 42.8% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 37.6% The company's stock price performance over the past 12 months beats the peer average by 60.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares, rose in value on Friday, November 26, with the stock price up by 1.33% to the previous day’s close as strong demand from buyers drove the stock to $19.97. Actively observing the price movement in the recent trading, the stock is buoying the session at $19.71, falling within a range … The Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Metrics You Need To Know Right Now Read More »

The trading price of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) closed lower on Monday, November 22, closing at $19.65, -30.98% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Aurinia Pharmaceuticals Inc. (AUPH) with the stream of -25.92% also noticed, India The Boeing Company (BA) encountered a rapid change of -2.20% in the last hour of Mondays trading session. The post Hair-raising Facts to Know: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), The Boeing Company (NYSE:BA) appeared first on Stocks Equity .

The post AUPH Stock Collapses As Offering Clouds Buyout Future appeared on BitcoinEthereumNews.com . Aurinia Pharmaceuticals (AUPH) filed a mixed-shelf offering, sending AUPH stock into a dive on Monday as investors questioned the validity of a rumored buyout. X The filing with the U.S.

Aurinia Pharma (AUPH) stock is taking a beating on Monday following a filing with the SEC after markets closed on Friday.

The company's recently filed unlimited shelf registration statement is making shareholders queasy.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) shares gapped down prior to trading on Monday . The stock had previously closed at $28.47, but opened at $23.93. Aurinia Pharmaceuticals shares last traded at $22.76, with a volume of 144,111 shares traded. AUPH has been the subject of several recent analyst reports. Oppenheimer boosted their price objective on []